# Aptar Pharma partners with CHI to commercialize Quattrii DPI platform

Aptar Pharma entered an exclusive collaboration agreement with Cambridge Healthcare Innovations (CHI) to lead the commercialization and promotion of the Quattrii Dry Powder Inhaler platform. Aptar will provide support for commercial manufacture and integration of its pharmaceutical services.

- Type: Partnership
- Announced: 2024-11-07
- Status: announced
- Products: dry powder inhaler platform
- Sectors: [Medical Devices](https://endata.com/sectors/medical-devices.md)

## Companies

- [Aptar Pharma](https://endata.com/companies/1969.md) (partner)
- [Cambridge Healthcare Innovations](https://endata.com/companies/81398.md) (partner)

## Sources

- [aptar.com](https://aptar.com/en-us/news-events/aptar-pharma-enters-into-exclusive-agreement-with-cambridge-healthcare-innovations-to-commercialize-the-quattrii-dry-powder-inhaler-platform), 2024-11-07: "Aptar Pharma today announced that it has entered into an exclusive collaboration agreement with Cambridge Healthcare Innovations (CHI) to lead the commercialization and promotion of its Quattrii Dry Powder Inhaler (DPI) platform."

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.